Evidence map›Paper›PMID 34788758›Full record

ArticleOncology2022

Variations in Radioiodine Therapy in Europe: Decision-Making after Total Thyroidectomy.

Flavio Forrer, Galina Farina Fischer, Ole Maas, Luca Giovanella, Martha Hoffmann, Ioannis Iakovou, Markus Luster, Jasna Mihailovic, Petra Petranovic Ovčariček, Alexis Vrachimis and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Endocrinology application of molecular imaging: current role of PET/CT.Journal of endocrinological investigation · 2024
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 7 countries.

Flavio ForrerDepartment of Radiology and Nuclear Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Galina Farina FischerDepartment of Radiology and Nuclear Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Ole MaasDepartment of Radiology and Nuclear Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Luca GiovanellaClinic for Nuclear Medicine and Competence Centre for Thyroid Diseases, Centre Imaging Institute of Southern Switzerland, Bellinzona, Switzerland.
Martha HoffmannDepartment of Nuclear Medicine, Radiology Centre, Vienna, Austria.
Ioannis IakovouAcademic Department of Nuclear Medicine, Aristotle University, Thessaloniki, Greece.
Markus LusterDepartment of Nuclear Medicine, University Hospital Marburg, Marburg, Germany.
Jasna MihailovicDepartment of Radiology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Petra Petranovic OvčaričekDepartment of Oncology and Nuclear Medicine, University Hospital Center "Sestre Milosrdnice", Zagreb, Croatia.
Alexis VrachimisDepartment of Nuclear Medicine, German Oncology Center, University Hospital of the European University, Limassol, Cyprus.
Slimane ZerdoudDepartment of Nuclear Medicine, University Cancer Center Toulouse Oncopole, Toulouse, France.
Paul Martin PutoraDepartment of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Kantonsspital St. Gallen · CHAristotle University of Thessaloniki · GREuropean Association of Nuclear Medicine · ATInstitut universitaire du cancer de Toulouse Oncopole · FRLaboratory for Biomedical Neurosciences · CHLimassol General Hospital · CYPhilipps University of Marburg · DEUniversity of Bern · CHUniversity of Novi Sad · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of radioiodine therapy (RIT) (used as ablation therapy or adjuvant therapy) following total thyroidectomy for differentiated thyroid cancer (DTC) changed. Major revisions of the American Thyroid Association (ATA) Guidelines in 2015 resulted in significant differences in treatment recommendations in comparison to the European Association of Nuclear Medicine (EANM) 2008 guidelines. Recently, we presented the effects on daily practice for RIT among Swiss Nuclear Medicine centres. We now performed a study at the European level and hypothesized that there is also considerable variability among European experts. We performed a decision-tree-based analysis of management strategies from all members of the EANM thyroid committee to map current practice among experts. We collected data on whether or not RIT is administered, on which criteria these decisions are based and collected details on treatment activities and patient preparation. Our study shows discrepancies for low-risk DTC, where "follow-up only" is recommended by some experts, while RIT with significant doses is used by other experts. E.g., for pT1b tumours without evidence of metastases, the level of agreement for the use of RIT is as low as 50%. If RIT is administered, activities of I-131 range from 1.1 GBq to 3.0 GBq. In other constellations (e.g., pT1a), experts diverge from current clinical guidelines as up to 75% administer RIT in certain cases. For intermediate and high-risk patients, RIT is generally recommended. However, dosing and treatment preparation (rhTSH vs. thyroid hormone withdrawal) vary distinctly. In comparison to the Swiss study, the general level of agreement is higher among the European experts. The recently proposed approach on the use of RIT, based on integrated post-surgery assessment (Martinique article) and results of ongoing prospective randomized studies are likely to reduce uncertainty in approaching RIT treatment. In certain constellations, consensus identified among European experts might be helpful in formulating future guidelines.

Indexed as

Clinical Decision-MakingCombined Modality TherapyConsensusDecision TreesDose Fractionation, RadiationEuropeHumansIodine RadioisotopesPractice Guidelines as TopicProspective StudiesThyroidectomyThyroid NeoplasmsIodine RadioisotopesDecision-makingRadioiodineRadioiodine therapyThyroid cancer

Identifiers

PMID34788758
PMCPMC8985029
OpenAlexW3211643852

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.